OPTIC: Opioid Policy Tools and Information Center | View in browser

Twitter Facebook

RAND-USC Schaeffer OPTIC

A National Resource for Opioid Policy Science

RAND Corporation logo

Note from the Director

Bradley Stein

Policymakers, regulators, and other stakeholders need to know which state policies are truly effective. However, determining if a policy actually caused changes in specific outcomes is fundamentally challenging. Not all policy evaluation studies are equally rigorous; some have major flaws in their analytic approach or limitations due to the data used.

Consistent with OPTIC’s mission to be a national resource, we have recently published a pragmatic guide to help decisionmakers determine how much they can trust the results of a health policy evaluation. Megan Schuler and her team focused on state policies because much of the public health-related policy action occurs at the state level. The guide offers a few rules of thumb to identify policy evaluations that provide strong evidence about whether there is a cause and effect relationship between a policy and an outcome. The guide also highlights some red flags indicating that a study’s findings should be viewed with caution.

The guide is a valuable contribution to our growing library of public goods including policy datasets, simulation tools, and specialized products. Please visit the OPTIC Policy Datasets page to see recent updates to available datasets such as: Naloxone Access laws through 2022, Good Samaritan laws through 2021, Office-Based Buprenorphine Treatment (OBBT) laws through 2019, and State Section 1115 IMD Exclusion Waivers data through 2020.

We always welcome your comments and suggestions at OPTIC@rand.org. – Bradley Stein, Director OPTIC

Recent Products from OPTIC Researchers

Close up of a person in a blue shirt reading a book, photo by smolaw11/Getty Images

Photo by smolaw11/Getty Images

A Pragmatic Guide for State Policymakers

This pragmatic guide helps decisionmakers determine how much they can trust the results of a health policy evaluation. Explore the guide »

Stethoscope and gavel on a law book, photo by Chinnapong/Getty Images

Photo by Chinnapong/Getty Images

Laws for Expanding Access to Medications for Opioid Use Disorder: A Legal Analysis of 16 States & Washington D.C.

This study reports on the results of a qualitative analysis that identified and categorized state medications for opioid use disorder related statutes and regulations in a stratified random sample of 16 states and Washington D.C. Read more »

A nurse checks the dosage on his digital tablet supervised by his staff nurse, photo by sturti/Getty Images

Photo by sturti/Getty Images

State Policies and Buprenorphine Prescribing by Nurse Practitioners and Physician Assistants

This cross-sectional study used pharmacy claims to examine the association of state policies with the odds of receiving buprenorphine treatment from a nurse practitioner or physician assistant versus a physician.
Read more »

Close up of a doctor writing a prescription, photo by wutwhanfoto/Getty Images

Photo by wutwhanfoto/Getty Images

An Exploratory Analysis of Differential Prescribing of High-Risk Opioids by Insurance Type Among Patients Seen by the Same Clinician

Clinicians prescribe high-risk opioid analgesics differently based on insurance type. The relationship between insurance and opioid prescribing quality goes beyond where patients receive care. Read more »

Medical team meeting, photo by sturti/Getty Images

Photo by sturti/Getty Images

Prior Authorization Restrictions on Medications for Opioid Use Disorder: Trends in State Laws from 2005 to 2019

Researchers conducted a review of U.S. regulations and statutes between 2005 and 2019 related to medications for opioid use disorder to identify the frequency and types of prior authorization prohibitions in state laws. Read more »

View All Publications »

Commentary and Press

Making Sense of Policy Evaluations for State Policymakers (Johns Hopkins Bloomberg School of Public Health)

Illegal Opioids are Hurting Too Many of Us, We Need a New Approach (RAND Corporation)

Pregnant People with Substance Use Disorders Need Treatment, Not Criminalization (STAT News)

Graphic of a prescription with two capsules in the bottom right corner signifying a prescription for buprenorphine.

From 2017 to 2018, the percentage of buprenorphine treatment episodes delivered by NPs and PAs increased from

4.6% to 12.8%

(RAND Corporation)

National Perspectives

A national sampling of thought-provoking research and insights

A Modified Delphi Process to Identify Experts' Perceptions of the Most Beneficial and Harmful Laws to Reduce Opioid-Related Harm - Hamilton et al. International Journal on Drug Policy

Association Between State Opioid Prescribing Cap Laws and Receipt of Opioid Prescriptions Among Children and Adolescents - Stone et al. JAMA Health Forum

Effects of Opioid Prescribing Cap Laws on Opioid and Other Pain Treatments Among Persons with Chronic Pain - McCourt et al. Journal of General Internal Medicine

Effects of State Opioid Prescribing Cap Laws on Opioid Prescribing after Surgery - Schmid et al. Health Services Research

Impact of Administering Buprenorphine to Overdose Survivors Using Emergency Medical Services - Carroll et al. Annals of Emergency Medicine

Laws Forbidding Pregnancy Discrimination in Substance Use Disorder Treatment Are Not Associated With Treatment Access - Davis et al. Journal of Addiction Medicine

Methadone-Involved Overdose Deaths in the U.S. Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs - Jones et al. JAMA Psychiatry

Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic - Tanz et al. JAMA Network Open

What Is a Propensity Score? Applications and Extensions of Balancing Score Methods - Stuart, E.A. Observational Studies

Forthcoming Presentations

April 28, 2023
Presenting on The Problem's Bigger than We Are: Understanding How Local Factors Influence Child Welfare Responses to Substance Use in Pregnancy, A Qualitative Study at the Pediatric Academic Societies Meeting (PAS) - Sarah Loch, Stephen Patrick, Bradley Stein

May 26, 2023
Presenting on Innovations in assessing bias and optimizing treatments at the 2023 American Causal Inference Conference (ACIC) - Beth Ann Griffin

May 30, 2023
RAND Europe hosting The International Society for the Study of Drug Policy (ISSDP) 2023 Conference

Leadership

Brad Stein

Bradley Stein

Director

Rosalie Liccardo Pacula

Rosalie Liccardo Pacula

Codirector

Beth Ann Griffin

Beth Ann Griffin

Codirector

 

OPTIC is designed to be a national resource, fostering innovative and high-quality research in opioid policy science, and developing and disseminating methods, tools, and information to the research community, policymakers, and other stakeholders.

https://www.rand.org/OPTIC

Follow RAND

Twitter Facebook LinkedIn Instagram

Privacy statement

RAND Corporation

RAND Corporation. 1776 Main Street, Santa Monica, CA 90401-3208.
RAND® is a registered trademark.